Dana Faratian

4.3k citations

59 papers · 2.2k indexed · h-index 27

Molecular Biology top 10%
Oncology top 5%
Cancer Research top 5%
Pulmonary and Respiratory Medicine top 10%
Genetics top 10%

Co-authors: David J. Harrison Simon P. Langdon Peter Mullen Jeremy Thomas Andrew H. Sims Charlene Kay John M.S. Bartlett Sarah J. Aitken
Topics: HER2/EGFR in Cancer Research (19 papers)Monoclonal and Polyclonal Antibodies Research (10 papers)Estrogen and related hormone effects (9 papers)
Cited by: Cancer Research Oncology Health, Toxicology and Mutagenesis
Journals: Journal of Clinical Oncology PLoS ONE Cancer Research
Partner nations: United Kingdom United States Japan

In The Last Decade

Dana Faratian

57 papers receiving 2.1k citations

Peers

Countries citing papers authored by Dana Faratian

Since Specialization

Citations

This map shows the geographic impact of Dana Faratian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dana Faratian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dana Faratian more than expected).

Fields of papers citing papers by Dana Faratian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dana Faratian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dana Faratian. The network helps show where Dana Faratian may publish in the future.

Co-authorship network of co-authors of Dana Faratian

This figure shows the co-authorship network connecting the top 25 collaborators of Dana Faratian. A scholar is included among the top collaborators of Dana Faratian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dana Faratian. Dana Faratian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Multi-Scale Genomic, Transcriptomic and Proteomic Analysis of Colorectal Cancer Cell Lines to Identify Novel Biomarkers 2015 ·PLoS ONE ·(unknown),In Hwa Um,Dana Faratian,Ying Zhou,Arran Turnbull,Simon P. Langdon,David J. Harrison	41
2	Increased STAT1 Signaling in Endocrine-Resistant Breast Cancer 2014 ·PLoS ONE ·Rui Huang,Dana Faratian,Andrew H. Sims,(unknown),Jeremy Thomas,David J. Harrison,Simon P. Langdon	32
3	Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer 2012 ·British Journal of Cancer ·Andrew H. Sims,Annelien J.M. Zweemer,Yoko Nagumo,Dana Faratian,Morwenna Muir,Michael Dodds,In Hwa Um,Charlene Kay,Max Hasmann,David J. Harrison,Simon P. Langdon	38
4	Proteomic analysis of pre- and post-sunitinib treated renal cancer tissue to assess tumor heterogeneity and differential protein expression. 2012 ·Journal of Clinical Oncology ·Grant D. Stewart,Fiach C. O’Mahony,Lél Eöry,Jyoti Nanda,Alexander Laird,Marie O’Donnell,Peter Mullen,Antony C. P. Riddick,Alan McNeill,Michael Aitchison,Daniel M. Berney,John Peters,Andrea Rockall,Anju Sahdev,Axel Bex,Dana Faratian,Simon Chowdhury,David J. Harrison,Ian M. Overton,Thomas Powles	2
5	Sprouty 2 Is an Independent Prognostic Factor in Breast Cancer and May Be Useful in Stratifying Patients for Trastuzumab Therapy 2011 ·PLoS ONE ·Dana Faratian,Andrew H. Sims,Peter Mullen,Charlene Kay,(unknown),Simon P. Langdon,David J. Harrison	41
6	Trastuzumab and Pertuzumab Produce Changes in Morphology and Estrogen Receptor Signaling in Ovarian Cancer Xenografts Revealing New Treatment Strategies 2011 ·Clinical Cancer Research ·Dana Faratian,Annelien J.M. Zweemer,Yoko Nagumo,Andrew H. Sims,Morwenna Muir,Michael Dodds,Peter Mullen,(unknown),Charlene Kay,Max Hasmann,David J. Harrison,Simon P. Langdon	44
7	Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor–positive early breast cancer patients 2011 ·Breast Cancer Research and Treatment ·Johanna G. H. van Nes,Esther M. de Kruijf,Hein Putter,Dana Faratian,Alison F. Munro,Fiona Campbell,Vincent T.H.B.M. Smit,Gerrit‐Jan Liefers,Peter J.K. Kuppen,Cornelis J.�H. van de Velde,John M.S. Bartlett	74
8	GnRH receptor activation competes at a low level with growth signaling in stably transfected human breast cell lines 2011 ·BMC Cancer ·Kevin Morgan,(unknown),(unknown),Andrew H. Sims,(unknown),Dana Faratian,David J. Harrison,Robert P. Millar,Simon P. Langdon	11
9	What can molecular pathology contribute to the management of renal cell carcinoma? 2011 ·Nature Reviews Urology ·Grant D. Stewart,Fiach C. O’Mahony,Thomas Powles,Antony C. P. Riddick,David J. Harrison,Dana Faratian	63
10	Tyrosine Phosphorylation Profiling Reveals the Signaling Network Characteristics of Basal Breast Cancer Cells 2010 ·Cancer Research ·Falko Hochgräfe,Luxi Zhang,Sandra O’Toole,Brigid C. Browne,Mark Pinese,(unknown),Gillian M. Lehrbach,David R. Croucher,Danny Rickwood,Alice Boulghourjian,Robert F. Shearer,Radhika Nair,Alexander Swarbrick,Dana Faratian,Peter Mullen,David J. Harrison,Andrew V. Biankin,Robert L. Sutherland,Mark J. Raftery,Roger J. Daly	141
11	A gene on the HER2 amplicon, C35, is an oncogene in breast cancer whose actions are prevented by inhibition of Syk 2010 ·British Journal of Cancer ·Elad Katz,(unknown),Andrew H. Sims,Dana Faratian,(unknown),Smith Eh,Jean A. Quinn,M. Edward,Richard R. Meehan,Elizabeth E. Evans,Simon P. Langdon,David J. Harrison	60
12	FACTORS DETERMINING GONADOTROPHIN RELEASING HORMONE ANALOGUE SENSITIVITY 2010 ·Annals of Oncology ·(unknown),Simon P. Langdon,Andrew H. Sims,(unknown),Dana Faratian,David J. Harrison	3
13	Systems Biology Reveals New Strategies for Personalizing Cancer Medicine and Confirms the Role of PTEN in Resistance to Trastuzumab 2009 ·Cancer Research ·Dana Faratian,Alexey Goltsov,(unknown),Anatoly Sorokin,Stuart Moodie,Peter Mullen,Charlene Kay,In Hwa Um,Simon P. Langdon,Igor Goryanin,David J. Harrison	126
14	Rapid screening of tissue microarrays for Her‐2 fluorescence in situ hybridization testing is an accurate, efficient and economic method of providing an entirely in situ hybridization‐based Her‐2 testing service 2009 ·Histopathology ·Dana Faratian,(unknown),Frances Rae,Jeremy Thomas	9
15	Automated image analysis for high‐throughput quantitative detection of ER and PR expression levels in large‐scale clinical studies: The TEAM Trial Experience 2009 ·Histopathology ·Dana Faratian,Charlene Kay,Tammy Robson,Fiona Campbell,Margaret Grant,(unknown),John M.S. Bartlett	44
16	Tissue microarray technology in the routine assessment of HER‐2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization 2008 ·Histopathology ·(unknown),Dana Faratian,Frances Rae,Jeremy Thomas	28
17	DCIS and aromatase inhibitors 2007 ·The Journal of Steroid Biochemistry and Molecular Biology ·J. Michael Dixon,Dana Faratian,Sharon White,Lorna Renshaw,Juliette Murray,Oliver Young,E. Jane Macaskill,Linda Williams,Jeremy Thomas,Dean B. Evans	6
18	Effects of fulvestrant 750 mg in premenopausal women with oestrogen-receptor-positive primary breast cancer 2007 ·European Journal of Cancer ·(unknown),Lorna Renshaw,E. Jane Macaskill,(unknown),Dana Faratian,James Thomas,J. Michael Dixon	55
19	Predictive markers in breast cancer – the future 2007 ·Histopathology ·Dana Faratian,J. M. S. Bartlett	30
20	A review of the pathology and management of uterine papillary serous carcinoma and correlation with outcome 2006 ·International Journal of Gynecological Cancer ·Dana Faratian,Alison Stillie,RMC Busby-Earle,V.J. Cowie,Hannah Monaghan	34

About Dana Faratian

Dana Faratian is a scholar working on Cancer Research, Oncology and Reproductive Medicine, having authored 59 papers that have together received 2.2k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (19 papers), Monoclonal and Polyclonal Antibodies Research (10 papers) and Estrogen and related hormone effects (9 papers). The work is most often cited by research in Cancer Research (557 citations), Oncology (879 citations) and Health, Toxicology and Mutagenesis (245 citations). Dana Faratian has collaborated with scholars based in United Kingdom, United States and Japan. Frequent co-authors include David J. Harrison, Simon P. Langdon, Peter Mullen, Jeremy Thomas, Andrew H. Sims, Charlene Kay, John M.S. Bartlett, Sarah J. Aitken, In Hwa Um and Alexey Goltsov. Their work appears in journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact